Diabetic Macular Edema - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Diabetic Macular Edema - Pipeline Review, H2 2018’, provides an overview of the Diabetic Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema

- The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects

- The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abpro

Aciont Inc

Acucela Inc

Aerie Pharmaceuticals Inc

Aldeyra Therapeutics Inc

Allergan Plc

Allgenesis Biotherapeutics Inc

Ampio Pharmaceuticals Inc

Araim Pharmaceuticals Inc

Boehringer Ingelheim GmbH ...

Abpro

Aciont Inc

Acucela Inc

Aerie Pharmaceuticals Inc

Aldeyra Therapeutics Inc

Allergan Plc

Allgenesis Biotherapeutics Inc

Ampio Pharmaceuticals Inc

Araim Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Cell Medica Ltd

Celon Pharma SA

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Clearside BioMedical Inc

Coherus BioSciences Inc

Daiichi Sankyo Co Ltd

Elasmogen Ltd

Exonate Ltd

EyeGate Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc

Eyevensys SAS

F. Hoffmann-La Roche Ltd

Formycon AG

Gene Signal International SA

Genmab A/S

Graybug Vision Inc

Isarna Therapeutics GmbH

Kalvista Pharmaceuticals Inc

Kowa Co Ltd

Lupin Ltd

Mabion SA

Momenta Pharmaceuticals Inc

Novartis AG

Ocular Therapeutix Inc

Oculis ehf

OcuNexus Therapeutics Inc

Ohr Pharmaceutical Inc

Pfizer Inc

Profarma

Protheragen Inc

Regeneron Pharmaceuticals Inc

Rezolute Inc

SciFluor Life Sciences LLC

Senju Pharmaceutical Co Ltd

Stealth BioTherapeutics Inc

ThromboGenics NV

Unity Biotechnology Inc

Verseon Corp

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Macular Edema - Overview 6

Diabetic Macular Edema - Therapeutics Development 7

Diabetic Macular Edema - Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Macular Edema - Overview 6

Diabetic Macular Edema - Therapeutics Development 7

Diabetic Macular Edema - Therapeutics Assessment 18

Diabetic Macular Edema - Companies Involved in Therapeutics Development 27

Diabetic Macular Edema - Drug Profiles 49

Diabetic Macular Edema - Dormant Projects 208

Diabetic Macular Edema - Discontinued Products 211

Diabetic Macular Edema - Product Development Milestones 212

Appendix 222

List of Tables

List of Tables

Number of Products under Development for Diabetic Macular Edema, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Diabetic Macular Edema, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Diabetic Macular Edema - Pipeline by Abpro, H2 2018

Diabetic Macular Edema - Pipeline by Aciont Inc, H2 2018

Diabetic Macular Edema - Pipeline by Acucela Inc, H2 2018

Diabetic Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Aldeyra Therapeutics Inc, H2 2018

Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2018

Diabetic Macular Edema - Pipeline by Allgenesis Biotherapeutics Inc, H2 2018

Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Celon Pharma SA, H2 2018

Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H2 2018

Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2018

Diabetic Macular Edema - Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Elasmogen Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Exonate Ltd, H2 2018

Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by EyePoint Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Eyevensys SAS, H2 2018

Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Formycon AG, H2 2018

Diabetic Macular Edema - Pipeline by Gene Signal International SA, H2 2018

Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2018

Diabetic Macular Edema - Pipeline by Graybug Vision Inc, H2 2018

Diabetic Macular Edema - Pipeline by Isarna Therapeutics GmbH, H2 2018

Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Kowa Co Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Lupin Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Mabion SA, H2 2018

Diabetic Macular Edema - Pipeline by Momenta Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Novartis AG, H2 2018

Diabetic Macular Edema - Pipeline by Ocular Therapeutix Inc, H2 2018

Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2018

Diabetic Macular Edema - Pipeline by OcuNexus Therapeutics Inc, H2 2018

Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc, H2 2018

Diabetic Macular Edema - Pipeline by Pfizer Inc, H2 2018

Diabetic Macular Edema - Pipeline by Profarma, H2 2018

Diabetic Macular Edema - Pipeline by Protheragen Inc, H2 2018

Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Diabetic Macular Edema - Pipeline by Rezolute Inc, H2 2018

Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H2 2018

Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H2 2018

Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc, H2 2018

Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2018

Diabetic Macular Edema - Pipeline by Unity Biotechnology Inc, H2 2018

Diabetic Macular Edema - Pipeline by Verseon Corp, H2 2018

Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2018

Diabetic Macular Edema - Dormant Projects, H2 2018

Diabetic Macular Edema - Dormant Projects, H2 2018 (Contd..1), H2 2018

Diabetic Macular Edema - Dormant Projects, H2 2018 (Contd..2), H2 2018

Diabetic Macular Edema - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Diabetic Macular Edema, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Diabetic Macular Edema, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports